GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mirum Pharmaceuticals Inc (NAS:MIRM) » Definitions » PS Ratio

Mirum Pharmaceuticals (Mirum Pharmaceuticals) PS Ratio : 5.60 (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Mirum Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Mirum Pharmaceuticals's share price is $25.065. Mirum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.48. Hence, Mirum Pharmaceuticals's PS Ratio for today is 5.60.

Good Sign:

Mirum Pharmaceuticals Inc stock PS Ratio (=5.5) is close to 3-year low of 5.32

The historical rank and industry rank for Mirum Pharmaceuticals's PS Ratio or its related term are showing as below:

MIRM' s PS Ratio Range Over the Past 10 Years
Min: 5.32   Med: 11.84   Max: 50.94
Current: 5.59

During the past 6 years, Mirum Pharmaceuticals's highest PS Ratio was 50.94. The lowest was 5.32. And the median was 11.84.

MIRM's PS Ratio is ranked better than
64.46% of 996 companies
in the Biotechnology industry
Industry Median: 9.095 vs MIRM: 5.59

Mirum Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $1.49. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $4.48.

During the past 12 months, the average Revenue per Share Growth Rate of Mirum Pharmaceuticals was 101.00% per year.

Back to Basics: PS Ratio


Mirum Pharmaceuticals PS Ratio Historical Data

The historical data trend for Mirum Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mirum Pharmaceuticals PS Ratio Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - 25.28 8.60 6.48

Mirum Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.60 9.01 8.33 8.47 6.48

Competitive Comparison of Mirum Pharmaceuticals's PS Ratio

For the Biotechnology subindustry, Mirum Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mirum Pharmaceuticals's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mirum Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Mirum Pharmaceuticals's PS Ratio falls into.



Mirum Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Mirum Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=25.065/4.476
=5.60

Mirum Pharmaceuticals's Share Price of today is $25.065.
Mirum Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.48.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Mirum Pharmaceuticals  (NAS:MIRM) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Mirum Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Mirum Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mirum Pharmaceuticals (Mirum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
950 Tower Lane, Suite 1050, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Executives
Peter Radovich officer: Chief Operating Officer C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Jolanda Howe officer: SVP, Global Controller C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Lara Longpre officer: Chief Development Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Pamela Vig officer: Chief Scientific Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Christopher Peetz director, officer: President and CEO C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080
Patrick J Heron director, 10 percent owner 550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Michael G Grey director, officer: Executive Chairman C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Eric Bjerkholt officer: Chief Financial Officer 132 PURDURE AVENUE, KENGSINGTON CA 94708
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Lon Cardon director C/O RENEO PHARMACEUTICALS, INC., 12230 EL CAMINO REAL, SUITE 230, SAN DIEGO CA 92130
Niall O'donnell director C/O RIVERVEST VENTURE PARTNERS, 101 SOUTH HANLEY RD., STE 1850, ST. LOUIS MO 63105
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Saira Ramasastry director 501 CANAL BLVD., RICHMOND CA 94804
Ian Clements officer: SVP Finance & Communications C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Edwin Jonathan Tucker officer: Chief Medical Officer C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404